09:49:23 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-02-17 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-17 Ordinarie utdelning CYXO 0.00 SEK
2022-05-16 Årsstämma 2022
2022-05-12 Kvartalsrapport 2022-Q1
2022-02-22 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-06-04 Ordinarie utdelning CYXO 0.00 SEK
2021-06-03 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-12 Bokslutskommuniké 2020
2020-11-13 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-06-05 Ordinarie utdelning CYXO 0.00 SEK
2020-06-04 Årsstämma 2020
2020-05-15 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-27 Ordinarie utdelning CYXO 0.00 SEK
2019-05-24 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-11-21 Kvartalsrapport 2018-Q3
2018-06-05 Årsstämma 2018
2018-05-24 Ordinarie utdelning CYXO 0.00 SEK
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-16 Bokslutskommuniké 2017
2017-12-11 Extra Bolagsstämma 2017
2017-10-25 Kvartalsrapport 2017-Q3
2017-08-30 Kvartalsrapport 2017-Q2
2017-05-24 Ordinarie utdelning CYXO 0.00 SEK
2017-05-23 Årsstämma 2017
2017-05-16 Kvartalsrapport 2017-Q1
2017-02-16 Bokslutskommuniké 2016
2016-10-28 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Cyxone är verksamma inom bioteknik. Bolagets specialistkompetens återfinns inom inom utveckling av läkemedel med fokus på växtprotein som bas. Läkemedlet ämnar användas främst i behandling utav immunrelaterade sjukdomar och produkterna baseras på cyclotidteknologi. Avsikten är att läkemedlet skall kunna användas vid behandling utav multipel skleros och reumatoid artrit. Cyxones huvudkontor ligger i Malmö.
2022-09-19 08:30:00

Cyxone (publ), a biotech company in autoimmune diseases, have received approvals from the Medical Product Agency (Office for Registration of Medicinal Products, Medical devices and Biocides) and the Central Ethics Committee in Poland to start a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).

"The approval is a very important milestone for us. Cyxone have now finally the possibility to initiate the greatest and foremost value-building activity ever in the company's history. Receiving this green light from Poland, which will be the most important country for the upcoming study, is really great and a big achievement. We are now looking forward to continuing working towards our goal to be able to offer a safe and user-friendly treatment which also contributes to improved quality of life for the patient," says Carl-Magnus Högerkorp, acting CEO, Cyxone.

The study is a multicenter, randomised, double-blinded, placebo-controlled clinical study where patients with moderate to severe RA, who have previously been treated with methotrexate with inadequate response, will be treated with Rabeximod for 24 weeks. The aim of the study is to confirm the therapeutic efficacy of Rabeximod in this patient population, as well as to expand the safety data documentation.

Rabeximod is a well-tolerated, orally available Phase 2 candidate drug with a unique mechanism of action. Rabeximod selectively targets the inflammatory macrophage, a type of white blood cell which is the central orchestrator of the inflammatory process that causes tissue destruction and clinical symptoms in RA. Combined with the convenience of oral administration and a beneficial tolerability profile, this opens up for treatment in the early as well as later stages of the disease. It is believed to be particularly effective at onset and relapses of RA, with good potential to prevent joint destruction and progression of the disease.

Contact

Carl-Magnus Högerkorp, acting CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com